Professor Zhang Wenhong explains that medical breakthroughs can shrink the gap between rich and poor patients. Take tuberculosis: China still has the world’s third‑largest TB burden, and in poorer regions the disease rate is ten times higher than in wealthy cities. A home‑grown short‑course pill, TB‑TRUST, cuts treatment to 6‑9 months, lifts cure rates above 80 %, and slashes the price to 30,000‑50,000 RMB. With an 80 % insurance reimbursement, a patient’s out‑of‑pocket cost can fall under 10,000 RMB. A similar story unfolded with hepatitis C. When the drug sofosbuvir first hit the U.S. market in 2013 it cost about $84,000 for a 12‑week course—far beyond most health systems’ reach. After the patent expired, prices fell dramatically. Egypt, once plagued by a 15 % infection rate, launched nationwide screening and subsidised treatment, driving the carrier rate down to 0.4 % by 2022. Zhang warns that new technologies—AI diagnostics, genetic testing, brain‑computer interfaces—could create fresh inequities if only the affluent can afford them. He calls for better digital literacy, clear responsibility rules, and policies that ensure anti‑aging and cognitive‑enhancement tools benefit everyone, not just a “super‑longevity” class. In short, innovation must be paired with fairness to truly improve public health.
Read moreChina’s medical‑equipment sector is racing ahead, turning cutting‑edge research into real‑world tools. In Chongqing, a new “problem‑fund” model lets companies pose challenges and finance solutions, while hospitals, universities and research institutes race to solve them. The city has also teamed up with Huawei to build a smart‑medical ecosystem. Shenzhen backs the push with a 40 billion‑yuan “fund + review” scheme, using the Greater Bay Area’s regulatory hub and national innovation platforms to help high‑end device makers scale quickly and reach global markets. The national promotion project for high‑end equipment entered its second year in 2025, with ministries coordinating funding, approvals and clinical adoption. Industry leaders say the game has changed: success now depends on the blend of hardware, AI algorithms and clinical data. Standardised frameworks let intelligent software and devices work together for a “1 + 1 > 2” effect. The result? A trillion‑yuan market, six national advanced‑manufacturing clusters, and Chinese‑made surgical robots that rank among the world’s top two in usage, now sold in more than 60 countries. Breakthroughs in 5G, quantum sensing and embodied intelligence are reshaping diagnosis and treatment. AI‑driven imaging auto‑positions scanners, cutting radiation and saving doctors’ time. Remote‑controlled surgical robots let surgeons in different continents operate a single patient together, breaking geographic barriers and expanding access to high‑quality care. By the end of the 14th Five‑Year Plan, China counted over 33,000 medical‑equipment firms—including 4,000 large‑scale players, 160 listed companies and nearly 700 nationally recognised “Little Giant” innovators—signalling a robust, technology‑driven future for global healthcare.
Read more